Browse CDK12

Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Nucleus speckle. Note=Colocalized with nuclear speckles throughout interphase.
Domain PF00069 Protein kinase domain
Function

Cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II (POLR2A), thereby acting as a key regulator of transcription elongation. Regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability. Preferentially phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation of MAP kinase activity, possibly leading to affect the response to estrogen inhibitors.

> Gene Ontology
 
Biological Process GO:0006397 mRNA processing
GO:0008380 RNA splicing
GO:0043405 regulation of MAP kinase activity
GO:0043484 regulation of RNA splicing
GO:0046777 protein autophosphorylation
GO:0070816 phosphorylation of RNA polymerase II C-terminal domain
GO:0071900 regulation of protein serine/threonine kinase activity
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004693 cyclin-dependent protein serine/threonine kinase activity
GO:0008353 RNA polymerase II carboxy-terminal domain kinase activity
GO:0030332 cyclin binding
GO:0097472 cyclin-dependent protein kinase activity
Cellular Component GO:0000307 cyclin-dependent protein kinase holoenzyme complex
GO:0002944 cyclin K-CDK12 complex
GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0019908 nuclear cyclin-dependent protein kinase holoenzyme complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDK12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDK12 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.02; FDR: 0.007470 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 4.28; FDR: 0.015 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDK12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2060.385
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5160.708
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0230.982
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0680.772
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.130.96
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.010.998
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2430.511
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2030.905
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2650.891
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1120.923
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9540.544
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0190.787
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDK12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDK12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDK12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDK12.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDK12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDK12 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDK12 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDK12
Namecyclin-dependent kinase 12
Aliases CRK7; CRKR; KIAA0904; CDC2 related protein kinase 7; CRKRS; Cdc2-related kinase, arginine/serine-rich; CDC2- ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDK12 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.